FDA
-
-
-
-
-
-
-
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
-
-
-
-
-
-
-
Harrow Announces First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
-
-
-
-
-
-
-
ImprimisRx Announces Leadership Changes
-
-
-
-
-
-
-
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
-
-
-
-
-
-
-
Harrow Health (HROW) Announces Transitional Pass-Through Reimbursement Status for TRIESENCE 40 mg/mL
-
-
-
-
-
-
-
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
-
328,603 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

